Animal Model Services Global Market - Forecast to 2025
The animal models services global market is expected to grow at single digit CAGR to reach $962.2 million by 2025. For hundreds of years, almost every medical breakthrough in human and animal health has been the result of research using animals. Animals in research are essential for the development of new and more effective methods for diagnosis and treatment of diseases that affect both humans and animals. Animals are used to learn more about health problems, and to assure the safety of new medical treatments.
Classical pharmacological models or animal models are used as a mandatory element in preclinical (toxicological and pharmacological) studies of new drugs. Although in recent years, the replacement of animal testing and animal models with in-vitro models has been increasingly introduced into practice, according to the modern manuals of pharmaco-toxicological preclinical study, some animal studies still remain compulsory.
For approval of the first phase clinical trials it is mandatory to submit preclinical pharmacological, toxicological and pharmacokinetic findings. Toxicology testing provides information about the conditions under which potentially useful for humans drugs may become toxic. These tests are used to assess the possible adverse reactions and the nature of the target organ. Other tests for determining the dosage range which define: the maximum dose at which no adverse effects are noticed; the lowest observed adverse effect level; the maximum feasible/tolerated dose (MFD/MTD), the therapeutic index as a ratio between LD50/ED50 also use animals at the preclinical stage. These animal studies are compared and extrapolated to determine relevant data for humans based on the animal species similarity to humans. Prior to testing in humans, results from animal models allow solely the formation of the untested hypothesis of human response. For example, if a compound shows lowering blood pressure activity in rats, the chances of such activity in humans are high. However, these approaches use of relatively large quantities of the new compound (usually around 5 g), and the required time and money. Furthermore, they also provide little or no information about the molecular mechanisms behind the observed effects.
Animal model studies have also been seen as an approach towards accidental discovery of drug effects discovered in clinical practice. For example, the diuretic effect of sulphanilamide and acetazolamide as carbonic anhydrase inhibitors; making them suitable for discovery of new biologics, as biologics are complex large compounds that are sometimes not well understood at molecular level. Animal models are biologically similar to humans and share a common physiology. They have a shorter life cycle making it convenient for study. Also, it is easy to control the animal environment, unlike that of humans. The success of animal model depends on animal model selection, which again depends on the species, breeds and strains, which have close resemblance with the humans.
Classical pharmacological models or animal models are used as a mandatory element in preclinical (toxicological and pharmacological) studies of new drugs. Although in recent years, the replacement of animal testing and animal models with in-vitro models has been increasingly introduced into practice, according to the modern manuals of pharmaco-toxicological preclinical study, some animal studies still remain compulsory.
For approval of the first phase clinical trials it is mandatory to submit preclinical pharmacological, toxicological and pharmacokinetic findings. Toxicology testing provides information about the conditions under which potentially useful for humans drugs may become toxic. These tests are used to assess the possible adverse reactions and the nature of the target organ. Other tests for determining the dosage range which define: the maximum dose at which no adverse effects are noticed; the lowest observed adverse effect level; the maximum feasible/tolerated dose (MFD/MTD), the therapeutic index as a ratio between LD50/ED50 also use animals at the preclinical stage. These animal studies are compared and extrapolated to determine relevant data for humans based on the animal species similarity to humans. Prior to testing in humans, results from animal models allow solely the formation of the untested hypothesis of human response. For example, if a compound shows lowering blood pressure activity in rats, the chances of such activity in humans are high. However, these approaches use of relatively large quantities of the new compound (usually around 5 g), and the required time and money. Furthermore, they also provide little or no information about the molecular mechanisms behind the observed effects.
Animal model studies have also been seen as an approach towards accidental discovery of drug effects discovered in clinical practice. For example, the diuretic effect of sulphanilamide and acetazolamide as carbonic anhydrase inhibitors; making them suitable for discovery of new biologics, as biologics are complex large compounds that are sometimes not well understood at molecular level. Animal models are biologically similar to humans and share a common physiology. They have a shorter life cycle making it convenient for study. Also, it is easy to control the animal environment, unlike that of humans. The success of animal model depends on animal model selection, which again depends on the species, breeds and strains, which have close resemblance with the humans.
1 ANIMAL MODEL SERVICES GLOBAL MARKET
1.1 EXECUTIVE SUMMARY
2 MARKET ANALYSIS
2.1 FACTORS INFLUENCING MARKET
2.1.1 DRIVERS AND OPPORTUNITIES
2.1.1.1 Need for preclinical studies for the approval of therapeutics
2.1.1.2 Complexity of biologics makes animal testing very important for safety data
2.1.1.3 Increased Investment in R&D by pharmaceutical companies is increasing the outsourcing
2.1.1.4 Genetic engineering advancements in the resent years will increase the use of animal models
2.1.1.5 Requirement of novel biologics therapeutics for certain diseases
2.1.2 RESTRAINTS AND THREATS
2.1.2.1 High cost of animal studies
2.1.2.2 Requirement of large number of animals for most studies
2.1.2.3 Ethical concerns and stringent regulations
2.1.2.4 Threat from alternatives
3 ANIMAL MODEL SERVICES
3.1 INTRODUCTION
3.1.1 Comparison Matrix of Animal Models and Applications
3.1.2 Small Animal models
3.1.3 Large Animal models
3.2 ETHICS AND REGULATIONS
3.3 ALTERNATIVES TO ANIMAL MODELS
3.4 OVERVIEW OF APPLICATIONS OF ANIMAL MODELS
3.5 MARKET SHARE ANALYSIS
3.6 COMPETITIVE LANDSCAPE
3.7 COMPANY DEVELOPMENTS
4 COMPANY PROFILES
4.1 ADVINUS THERAPEUTICS
4.1.1 OVERVIEW
4.1.2 FINANCIALS
4.1.3 SERVICE PORTFOLIO
4.1.4 KEY DEVELOPMENTS
4.1.5 SWOT ANALYSIS
4.2 BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
4.2.1 OVERVIEW
4.2.2 FINANCIALS
4.2.3 SERVICE PORTFOLIO
4.2.4 KEY DEVELOPMENTS
4.2.5 SWOT ANALYSIS
4.3 CHARLES RIVER LABORATORIES
4.3.1 OVERVIEW
4.3.2 FINANCIALS
4.3.3 SERVICE PORTFOLIO
4.3.4 KEY DEVELOPMENTS
4.3.5 SWOT ANALYSIS
4.4 CROWN BIOSCIENCES
4.4.1 OVERVIEW
4.4.2 FINANCIALS
4.4.3 SERVICE PORTFOLIO
4.4.4 KEY DEVELOPMENTS
4.4.5 SWOT ANALYSIS
4.5 ENVIGO
4.5.1 OVERVIEW
4.5.2 FINANCIALS
4.5.3 SERVICE PORTFOLIO
4.5.4 KEY DEVELOPMENTS
4.5.5 SWOT ANALYSIS
4.6 GENOWAY
4.6.1 OVERVIEW
4.6.2 FINANCIALS
4.6.3 SERVICE PORTFOLIO
4.6.4 KEY DEVELOPMENTS
4.6.5 SWOT ANALYSIS
4.7 HORIZON DISCOVERY GROUP, PLC
4.7.1 OVERVIEW
4.7.2 FINANCIALS
4.7.3 SERVICE PORTFOLIO
4.7.4 KEY DEVELOPMENTS
4.7.5 SWOT ANALYSIS
4.8 JACKSON LABORATORY
4.8.1 OVERVIEW
4.8.2 FINANCIALS
4.8.3 SERVICE PORTFOLIO
4.8.4 KEY DEVELOPMENTS
4.8.5 SWOT ANALYSIS
4.9 PHARMALEGACY BIOTECHNOLOGY
4.9.1 OVERVIEW
4.9.2 FINANCIALS
4.9.3 SERVICE PORTFOLIO
4.9.4 KEY DEVELOPMENTS
4.9.5 SWOT ANALYSIS
4.10 PHARMARON
4.10.1 OVERVIEW
4.10.2 FINANCIALS
4.10.3 SERVICE PORTFOLIO
4.10.4 KEY DEVELOPMENTS
4.10.5 SWOT ANALYSIS
4.11 PSYCHOGENICS INC
4.11.1 OVERVIEW
4.11.2 FINANCIALS
4.11.3 SERVICE PORTFOLIO
4.11.4 KEY DEVELOPMENTS
4.11.5 SWOT ANALYSIS
4.12 SHANGHAI MEDICILON
4.12.1 OVERVIEW
4.12.2 FINANCIALS
4.12.3 SERVICE PORTFOLIO
4.12.4 KEY DEVELOPMENTS
4.12.5 SWOT ANALYSIS
4.13 SOBRAN INC
4.13.1 OVERVIEW
4.13.2 FINANCIALS
4.13.3 SERVICE PORTFOLIO
4.13.4 KEY DEVELOPMENTS
4.13.5 SWOT ANALYSIS
4.14 SYNGENE INTERNATIONAL
4.14.1 OVERVIEW
4.14.2 FINANCIALS
4.14.3 SERVICE PORTFOLIO
4.14.4 KEY DEVELOPMENTS
4.14.5 SWOT ANALYSIS
4.15 TACONIC BIOSCIENCES
4.15.1 OVERVIEW
4.15.2 FINANCIALS
4.15.3 SERVICE PORTFOLIO
4.15.4 KEY DEVELOPMENTS
4.15.5 SWOT ANALYSIS
4.16 WUXI APPTEC
4.16.1 OVERVIEW
4.16.2 FINANCIALS
4.16.3 SERVICE PORTFOLIO
4.16.4 KEY DEVELOPMENTS
4.16.5 SWOT ANALYSIS
1.1 EXECUTIVE SUMMARY
2 MARKET ANALYSIS
2.1 FACTORS INFLUENCING MARKET
2.1.1 DRIVERS AND OPPORTUNITIES
2.1.1.1 Need for preclinical studies for the approval of therapeutics
2.1.1.2 Complexity of biologics makes animal testing very important for safety data
2.1.1.3 Increased Investment in R&D by pharmaceutical companies is increasing the outsourcing
2.1.1.4 Genetic engineering advancements in the resent years will increase the use of animal models
2.1.1.5 Requirement of novel biologics therapeutics for certain diseases
2.1.2 RESTRAINTS AND THREATS
2.1.2.1 High cost of animal studies
2.1.2.2 Requirement of large number of animals for most studies
2.1.2.3 Ethical concerns and stringent regulations
2.1.2.4 Threat from alternatives
3 ANIMAL MODEL SERVICES
3.1 INTRODUCTION
3.1.1 Comparison Matrix of Animal Models and Applications
3.1.2 Small Animal models
3.1.3 Large Animal models
3.2 ETHICS AND REGULATIONS
3.3 ALTERNATIVES TO ANIMAL MODELS
3.4 OVERVIEW OF APPLICATIONS OF ANIMAL MODELS
3.5 MARKET SHARE ANALYSIS
3.6 COMPETITIVE LANDSCAPE
3.7 COMPANY DEVELOPMENTS
4 COMPANY PROFILES
4.1 ADVINUS THERAPEUTICS
4.1.1 OVERVIEW
4.1.2 FINANCIALS
4.1.3 SERVICE PORTFOLIO
4.1.4 KEY DEVELOPMENTS
4.1.5 SWOT ANALYSIS
4.2 BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
4.2.1 OVERVIEW
4.2.2 FINANCIALS
4.2.3 SERVICE PORTFOLIO
4.2.4 KEY DEVELOPMENTS
4.2.5 SWOT ANALYSIS
4.3 CHARLES RIVER LABORATORIES
4.3.1 OVERVIEW
4.3.2 FINANCIALS
4.3.3 SERVICE PORTFOLIO
4.3.4 KEY DEVELOPMENTS
4.3.5 SWOT ANALYSIS
4.4 CROWN BIOSCIENCES
4.4.1 OVERVIEW
4.4.2 FINANCIALS
4.4.3 SERVICE PORTFOLIO
4.4.4 KEY DEVELOPMENTS
4.4.5 SWOT ANALYSIS
4.5 ENVIGO
4.5.1 OVERVIEW
4.5.2 FINANCIALS
4.5.3 SERVICE PORTFOLIO
4.5.4 KEY DEVELOPMENTS
4.5.5 SWOT ANALYSIS
4.6 GENOWAY
4.6.1 OVERVIEW
4.6.2 FINANCIALS
4.6.3 SERVICE PORTFOLIO
4.6.4 KEY DEVELOPMENTS
4.6.5 SWOT ANALYSIS
4.7 HORIZON DISCOVERY GROUP, PLC
4.7.1 OVERVIEW
4.7.2 FINANCIALS
4.7.3 SERVICE PORTFOLIO
4.7.4 KEY DEVELOPMENTS
4.7.5 SWOT ANALYSIS
4.8 JACKSON LABORATORY
4.8.1 OVERVIEW
4.8.2 FINANCIALS
4.8.3 SERVICE PORTFOLIO
4.8.4 KEY DEVELOPMENTS
4.8.5 SWOT ANALYSIS
4.9 PHARMALEGACY BIOTECHNOLOGY
4.9.1 OVERVIEW
4.9.2 FINANCIALS
4.9.3 SERVICE PORTFOLIO
4.9.4 KEY DEVELOPMENTS
4.9.5 SWOT ANALYSIS
4.10 PHARMARON
4.10.1 OVERVIEW
4.10.2 FINANCIALS
4.10.3 SERVICE PORTFOLIO
4.10.4 KEY DEVELOPMENTS
4.10.5 SWOT ANALYSIS
4.11 PSYCHOGENICS INC
4.11.1 OVERVIEW
4.11.2 FINANCIALS
4.11.3 SERVICE PORTFOLIO
4.11.4 KEY DEVELOPMENTS
4.11.5 SWOT ANALYSIS
4.12 SHANGHAI MEDICILON
4.12.1 OVERVIEW
4.12.2 FINANCIALS
4.12.3 SERVICE PORTFOLIO
4.12.4 KEY DEVELOPMENTS
4.12.5 SWOT ANALYSIS
4.13 SOBRAN INC
4.13.1 OVERVIEW
4.13.2 FINANCIALS
4.13.3 SERVICE PORTFOLIO
4.13.4 KEY DEVELOPMENTS
4.13.5 SWOT ANALYSIS
4.14 SYNGENE INTERNATIONAL
4.14.1 OVERVIEW
4.14.2 FINANCIALS
4.14.3 SERVICE PORTFOLIO
4.14.4 KEY DEVELOPMENTS
4.14.5 SWOT ANALYSIS
4.15 TACONIC BIOSCIENCES
4.15.1 OVERVIEW
4.15.2 FINANCIALS
4.15.3 SERVICE PORTFOLIO
4.15.4 KEY DEVELOPMENTS
4.15.5 SWOT ANALYSIS
4.16 WUXI APPTEC
4.16.1 OVERVIEW
4.16.2 FINANCIALS
4.16.3 SERVICE PORTFOLIO
4.16.4 KEY DEVELOPMENTS
4.16.5 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
TABLE 2 MAJOR TYPES OF GENETICALLY ENGINEERED AND TRANSPLANTATION ANIMAL MODELS
TABLE 3 TYPICAL PRECLINICAL ISSUES OF BIOLOGICS
TABLE 4 ANIMAL MODEL SERVICE GLOBAL MARKET BY REGION ($MN)
TABLE 5 ANIMAL MODEL SERVICE GLOBAL MARKET BY TYPE OF ANIMAL SPECIES ($MN)
TABLE 6 ANIMAL MODEL SERVICE GLOBAL MARKET BY APPLICATION ($MN)
TABLE 7 ANIMAL MODEL SERVICE COST (DEVELOPMENT OF TRANSGENIC MOUSE)
TABLE 8 ANIMAL MODEL SERVICE COST (BASED ON DISEASE MODELS)
TABLE 9 ANIMAL MODEL SERVICE COST (IMAGING SERVICE COST BY AN ACADEMIC INSTITUTION)
TABLE 10 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE THERAPEUTIC AREAS
TABLE 11 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE IMMUNOLOGY/INFLAMMATION THERAPEUTIC AREAS
TABLE 12 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE FIBROSIS THERAPEUTIC AREAS
TABLE 13 COMPANY DEVELOPMENTS
TABLE 14 CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 15 CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 16 CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 17 GENOWAY: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
TABLE 18 HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 19 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 20 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 21 SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 22 SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 23 WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 1 COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
TABLE 2 MAJOR TYPES OF GENETICALLY ENGINEERED AND TRANSPLANTATION ANIMAL MODELS
TABLE 3 TYPICAL PRECLINICAL ISSUES OF BIOLOGICS
TABLE 4 ANIMAL MODEL SERVICE GLOBAL MARKET BY REGION ($MN)
TABLE 5 ANIMAL MODEL SERVICE GLOBAL MARKET BY TYPE OF ANIMAL SPECIES ($MN)
TABLE 6 ANIMAL MODEL SERVICE GLOBAL MARKET BY APPLICATION ($MN)
TABLE 7 ANIMAL MODEL SERVICE COST (DEVELOPMENT OF TRANSGENIC MOUSE)
TABLE 8 ANIMAL MODEL SERVICE COST (BASED ON DISEASE MODELS)
TABLE 9 ANIMAL MODEL SERVICE COST (IMAGING SERVICE COST BY AN ACADEMIC INSTITUTION)
TABLE 10 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE THERAPEUTIC AREAS
TABLE 11 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE IMMUNOLOGY/INFLAMMATION THERAPEUTIC AREAS
TABLE 12 COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE FIBROSIS THERAPEUTIC AREAS
TABLE 13 COMPANY DEVELOPMENTS
TABLE 14 CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 15 CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 16 CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 17 GENOWAY: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
TABLE 18 HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 19 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 20 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 21 SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 22 SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 23 WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
LIST OF FIGURES
FIGURE 1 MARKET DYNAMICS
FIGURE 2 GENOME COMPARISON
FIGURE 3 ANIMAL PROFILES
FIGURE 4 COMMON ANIMAL MODELS
FIGURE 5 ADVANTAGES AND DISADVANTAGES OF RODENT MODELS
FIGURE 6 ADVANTAGES AND DISADVANTAGES OF NHP
FIGURE 7 PRINCIPLES OF 3RS
FIGURE 8 PERCENTAGE OF ANIMALS USED IN DIFFRENT STAGES OF PHARMACUTICAL DEVELOPMENT
FIGURE 9 ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
FIGURE 10 ANIMAL MODEL SERVICE GLOBAL MARKET, BY TYPE OF ANIMAL SPECIES ($MN, %)
FIGURE 11 ANIMAL MODEL SERVICE GLOBAL MARKET, BY APPLICATION ($MN, %)
FIGURE 12 ANIMAL MODEL SERVICE GLOBAL MARKET SHARE (%)
FIGURE 13 COMPANY DEVELOPMENTS
FIGURE 14 SWOT: ADVINUS THERAPEUTICS
FIGURE 15 SWOT: BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
FIGURE 16 OVERVIEW: CHARLES RIVER LABORATORIES
FIGURE 17 SWOT: CHARLES RIVER LABORATORIES
FIGURE 18 SWOT: CROWN BIOSCIENCES
FIGURE 19 SWOT: ENVIGO
FIGURE 20 OVERVIEW: GENOWAY
FIGURE 21 SWOT: GENOWAY
FIGURE 22 OVERVIEW: HORIZON DISCOVERY GROUP, PLC
FIGURE 23 SWOT: HORIZON DISCOVERY GROUP, PLC
FIGURE 24 SWOT: JACKSON LABORATORY
FIGURE 25 SWOT: PHARMALEGACY
FIGURE 26 SWOT: PHARMARON
FIGURE 27 SWOT: PSYCOGENICS INC
FIGURE 28 SWOT: SHANGHAI MEDICILON
FIGURE 29 SWOT: SOBRAN BIOSCIENCES
FIGURE 30 OVERVIEW: SYNGENE INTERNATIONAL
FIGURE 31 SWOT: SYNGENE INTERNATIONAL
FIGURE 32 SWOT: TACONIC BIOSCIENCES
FIGURE 33 SWOT: WUXI APPTEC
FIGURE 1 MARKET DYNAMICS
FIGURE 2 GENOME COMPARISON
FIGURE 3 ANIMAL PROFILES
FIGURE 4 COMMON ANIMAL MODELS
FIGURE 5 ADVANTAGES AND DISADVANTAGES OF RODENT MODELS
FIGURE 6 ADVANTAGES AND DISADVANTAGES OF NHP
FIGURE 7 PRINCIPLES OF 3RS
FIGURE 8 PERCENTAGE OF ANIMALS USED IN DIFFRENT STAGES OF PHARMACUTICAL DEVELOPMENT
FIGURE 9 ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
FIGURE 10 ANIMAL MODEL SERVICE GLOBAL MARKET, BY TYPE OF ANIMAL SPECIES ($MN, %)
FIGURE 11 ANIMAL MODEL SERVICE GLOBAL MARKET, BY APPLICATION ($MN, %)
FIGURE 12 ANIMAL MODEL SERVICE GLOBAL MARKET SHARE (%)
FIGURE 13 COMPANY DEVELOPMENTS
FIGURE 14 SWOT: ADVINUS THERAPEUTICS
FIGURE 15 SWOT: BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
FIGURE 16 OVERVIEW: CHARLES RIVER LABORATORIES
FIGURE 17 SWOT: CHARLES RIVER LABORATORIES
FIGURE 18 SWOT: CROWN BIOSCIENCES
FIGURE 19 SWOT: ENVIGO
FIGURE 20 OVERVIEW: GENOWAY
FIGURE 21 SWOT: GENOWAY
FIGURE 22 OVERVIEW: HORIZON DISCOVERY GROUP, PLC
FIGURE 23 SWOT: HORIZON DISCOVERY GROUP, PLC
FIGURE 24 SWOT: JACKSON LABORATORY
FIGURE 25 SWOT: PHARMALEGACY
FIGURE 26 SWOT: PHARMARON
FIGURE 27 SWOT: PSYCOGENICS INC
FIGURE 28 SWOT: SHANGHAI MEDICILON
FIGURE 29 SWOT: SOBRAN BIOSCIENCES
FIGURE 30 OVERVIEW: SYNGENE INTERNATIONAL
FIGURE 31 SWOT: SYNGENE INTERNATIONAL
FIGURE 32 SWOT: TACONIC BIOSCIENCES
FIGURE 33 SWOT: WUXI APPTEC
